Sanofi Reports Positive Results in Phase 3 Trials of Dupixent
26 February 2019 - 5:40AM
Dow Jones News
By Stephen Nakrosis
Sanofi (SNY) on Monday reported positive results from a Phase 3
trial of Dupixent, a treatment for patients suffering from severe
chronic rhinosinusitis with nasal polyps.
The condition causes severe swelling of the sinus cavities, and
may lead to pain, breathing difficulties and a loss of taste and
smell.
The company said the two trials, SINUS-24 and SINUS-52,
demonstrated Dupixent, or dupilumab, significantly reduced chronic
sinus disease. When added to the standard of care nasal spray, the
treatment improved nasal polyp size, nasal congestion severity,
chronic sinus disease, sense of smell and co-morbid asthma
outcomes, Sanofi said.
Overall, rates of adverse events were generally similar between
the Dupixent-treated group and placebo, the company said.
-Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
February 25, 2019 13:25 ET (18:25 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2024 to May 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From May 2023 to May 2024